期刊
CELLULAR AND MOLECULAR LIFE SCIENCES
卷 79, 期 4, 页码 -出版社
SPRINGER BASEL AG
DOI: 10.1007/s00018-022-04225-1
关键词
Colony stimulating factor-1 receptor; Alzheimer's disease; Parkinson's disease; Huntington's disease; Amyotrophic lateral sclerosis; Multiple sclerosis
资金
- Karolinska Institute
- Swedish Medical Research Council
- Neuroforbundet
- Alltid Lite Sterkere
- HjarnFonden
- AlzheimerFonden
- BarnCancerFonden
- Mayo Clinic Center for Regenerative Medicine
- Donald G. and Jodi P. Heeringa Family
- Haworth Family Professorship in Neurodegenerative Diseases Fund
- The Albertson Parkinson's Research Foundation
- NIH [R01NS091519, U54 HD090260, P30CA013330]
This review article summarizes the recent advances in the use of CSF-1R inhibitors for treating neurodegenerative diseases and discusses potential challenges for clinical application.
Microglia are specialized dynamic immune cells in the central nervous system (CNS) that plays a crucial role in brain homeostasis and in disease states. Persistent neuroinflammation is considered a hallmark of many neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and primary progressive multiple sclerosis (MS). Colony stimulating factor 1-receptor (CSF-1R) is predominantly expressed on microglia and its expression is significantly increased in neurodegenerative diseases. Cumulative findings have indicated that CSF-1R inhibitors can have beneficial effects in preclinical neurodegenerative disease models. Research using CSF-1R inhibitors has now been extended into non-human primates and humans. This review article summarizes the most recent advances using CSF-1R inhibitors in different neurodegenerative conditions including AD, PD, HD, ALS and MS. Potential challenges for translating these findings into clinical practice are presented.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据